Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

Developed by Genentech, Herceptin kills cancer cells carrying excess HER2. But even though Herceptin was approved as a breast cancer treatment by the U.S. Food and Drug Administration in September ...

Trastuzumab (or, Herceptin) works best when it's given with cancer-killing drugs, certain chemotherapies, and it has been a very significant advance. Now we measure HER2 by looking at the tissue ...

The FDA will allow Herceptin, a biological cancer drug, to be used to treat an aggressive type of breast cancer after surgery. According to the FDA decision, announced yesterday, Herceptin may now ...

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab. Cancer Res , February 26, 2013 DOI: 10.1158/0008-5472.CAN-12-3349 ...

If you have early-stage HER2-positive breast cancer, here’s good news: There are more treatment options than ever. They can help you live longer while you enjoy a good quality of life.

“Over the past 20 years, Herceptin has significantly advanced treatment of HER2-positive breast cancer,” said Sandra Horning, MD, chief medical officer and head of Global Product Development.

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal Growth Factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not ...

In 1998, Herceptin (trastuzumab), the first medication to directly target HER2, was approved by the FDA. Oncologists usually start with this drug before trying other treatments.

The breast cancer drug Herceptin prevents breast cancer from coming back in some women, new research shows. Moreover, Herceptin works just as well with and without Adriamycin, a chemotherapy drug ...

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results. When ...

The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with HER2-overexpressing malignancies, according to a press release from the agent&rsquo ...